FDA requires eye risk warnings on Ozempic, Zepbound and other GLP-1 drugs

Key facts

• The FDA said it informed patients and healthcare providers of a potential increased risk of a serious eye condition with GLP-1 drugs.
• The labeling change covers non-arteritic anterior ischemic optic neuropathy (NAION), which the FDA described as a common cause of sudden, painless vision loss.
• The FDA named Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy among the GLP-1 drugs affected.

The US Food and Drug Administration said on November 9 that it is requiring GLP-1 drugs used for weight loss and diabetes to add information about a potential increased risk of a serious eye condition to the "warnings and precautions" section of their labeling.

The agency said the labeling change covers non-arteritic anterior ischemic optic neuropathy (NAION), which it described as a common cause of sudden, painless vision loss. The FDA said it informed patients and healthcare providers of the potential increased risk.

The requirement applies to GLP-1 drugs including Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy, the FDA said.